For people with mild to severe atopic dermatitis, short-term application of Crisaborole 2% ointment is safe and effective.

The goal of a systematic review and meta-analysis was to provide a thorough evaluation of the use of Crisaborole in mild to moderate atopic dermatitis.

Only randomized controlled trials contrasting the administration of Crisaborole two times a day to a vehicle or other active therapy in individuals with mild to moderate atopic dermatitis were considered. The HOME initiative's advice served as the basis for the selection of results. Using the proper assessment tools, the safety of Crisaborole as well as patient-reported symptoms, clinician-reported indicators, and health-related quality of life were all evaluated.

In the pooled analysis, 8 randomized controlled trials (RCTs) with 2266 subjects were incorporated. Subjects receiving Crisaborole experienced larger improvements than those receiving the vehicle in the following measures throughout the course of the 4-week treatment: Numerical Rating Scale (NRS) (mean difference [MD] -0.70), Patient-oriented eczema measure (POEM) (MD -3.50), Eczema Area and Severity Index (EASI) (MD -14.49%), Investigator’s Static Global Assessment (ISGA) (relative risk [RR] 1.45), Dermatology Life Quality Index (DLQI) (MD -1.54), and Dermatitis Family Impact Questionnaire (DFI) (MD -1.16).

When Crisaborole was administered, more patients attained EASI 75 ( RR 1.71). No discernible difference was noted in terms of occurrence of adverse events (RR 1.12), serious adverse events  (RR 1.89), or withdrawal due to adverse events (RR 0.87) between the two regimens. Moreover, 1 RCT compared the effects of Crisaborole and Pimecrolimus, claiming that most time points showed no discernible difference in the enhancement of EASI or NRS.

Crisaborole has a good safety profile and is an effective topical medication for the treatment of mild to severe atopic dermatitis. Additionally, Crisaborole has a similar practical effectiveness as Pimecrolimus.